Biosimilar Interchangeability and Substitution in the US: What Comes Next?
The American Journal of Managed Care · 01.04.2026 · 32 (4) · 198
DOI: 10.37765/ajmc.2026.89826 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Journal of Managed Care, online erschienen am 20.10.2025. Verfasst von Benjamin N Rome und 2 weiteren Autor:innen. Beteiligte Einrichtung: Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Wo…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Drug Substitution.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont St, Ste 3030,…
- Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Zitieren
APA
Rome, B. N., Bhaskar, A., & Kesselheim, A. S. (2026). Biosimilar Interchangeability and Substitution in the US: What Comes Next?. The American Journal of Managed Care, 32(4), 198. https://doi.org/10.37765/ajmc.2026.89826
Vancouver
Rome BN, Bhaskar A, Kesselheim AS. Biosimilar Interchangeability and Substitution in the US: What Comes Next?. The American Journal of Managed Care. 2026;32(4):198. doi:10.37765/ajmc.2026.89826
BibTeX
@article{Rome2026,
author = {Rome, Benjamin N and Bhaskar, Anushka and Kesselheim, Aaron S},
title = {Biosimilar Interchangeability and Substitution in the US: What Comes Next?},
journal = {The American Journal of Managed Care},
year = {2026},
volume = {32},
number = {4},
pages = {198},
doi = {10.37765/ajmc.2026.89826}
}
EUVIMED